Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Lusk CM, Watza D, Dyson G, Craig D, Ratliff V, Wenzlaff AS, Lonardo F, Bollig-Fischer A, Bepler G, Purrington K, Gadgeel S, Schwartz AG.

Clin Cancer Res. 2019 Jul 15;25(14):4300-4308. doi: 10.1158/1078-0432.CCR-18-2439. Epub 2019 Apr 12.

PMID:
30979741
2.

HDAC6 regulates DNA damage response via deacetylating MLH1.

Zhang M, Hu C, Moses N, Haakenson J, Xiang S, Quan D, Fang B, Yang Z, Bai W, Bepler G, Li GM, Zhang XM.

J Biol Chem. 2019 Apr 12;294(15):5813-5826. doi: 10.1074/jbc.RA118.006374. Epub 2019 Feb 15.

PMID:
30770470
3.

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.

4.

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.

Heyza JR, Lei W, Watza D, Zhang H, Chen W, Back JB, Schwartz AG, Bepler G, Patrick SM.

Clin Cancer Res. 2019 Apr 15;25(8):2523-2536. doi: 10.1158/1078-0432.CCR-18-3094. Epub 2018 Dec 11.

PMID:
30538112
5.

Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor.

Patki M, McFall T, Rosati R, Huang Y, Malysa A, Polin L, Fielder A, Wilson MR, Lonardo F, Back J, Li J, Matherly LH, Bepler G, Ratnam M.

Sci Rep. 2018 Oct 30;8(1):16006. doi: 10.1038/s41598-018-34475-8.

6.

Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes.

Watza D, Lusk CM, Dyson G, Purrington KS, Chen K, Wenzlaff AS, Ratliff V, Neslund-Dudas C, Bepler G, Schwartz AG.

Carcinogenesis. 2018 Dec 31;39(12):1447-1454. doi: 10.1093/carcin/bgy119.

7.

A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.

Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, Bepler G, Iyer AK, Singh M, Rishi AK.

Oncotarget. 2018 Jul 3;9(51):29680-29697. doi: 10.18632/oncotarget.25671. eCollection 2018 Jul 3.

8.

RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Chammaa M, Malysa A, Redondo C, Jang H, Chen W, Bepler G, Fernandez-Valdivia R.

J Cell Physiol. 2018 Dec;233(12):9548-9562. doi: 10.1002/jcp.26858. Epub 2018 Jun 28.

9.

Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.

Wu JY, Xiang S, Zhang M, Fang B, Huang H, Kwon OK, Zhao Y, Yang Z, Bai W, Bepler G, Zhang XM.

J Biol Chem. 2018 Feb 9;293(6):1976-1993. doi: 10.1074/jbc.M117.795955. Epub 2017 Dec 19.

10.

A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.

Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22856. No abstract available.

11.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H.

Pancreas. 2016 Nov;45(10):1485-1493.

12.

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.

Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072.

13.

Standardizing Assessment of Competences and Competencies of Oncology Nurses Working in Ambulatory Care.

Beaver C, Magnan MA, Henderson D, DeRose P, Carolin K, Bepler G.

J Nurses Prof Dev. 2016 Mar-Apr;32(2):64-73; quiz E6. doi: 10.1097/NND.0000000000000250.

14.

Ubiquitin-specific Peptidase 10 (USP10) Deubiquitinates and Stabilizes MutS Homolog 2 (MSH2) to Regulate Cellular Sensitivity to DNA Damage.

Zhang M, Hu C, Tong D, Xiang S, Williams K, Bai W, Li GM, Bepler G, Zhang X.

J Biol Chem. 2016 May 13;291(20):10783-91. doi: 10.1074/jbc.M115.700047. Epub 2016 Mar 14.

15.

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.

Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A.

Clin Cancer Res. 2016 May 15;22(10):2396-404. doi: 10.1158/1078-0432.CCR-15-1468. Epub 2015 Dec 15.

16.

RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis.

Zheng SD, Bui K, Chiappori A, Bepler G, Bui MM.

Pathol Oncol Res. 2016 Jul;22(3):477-82. doi: 10.1007/s12253-015-0021-x. Epub 2015 Nov 26.

17.

Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry.

Wu J, Zhang Y, Wiegand R, Wang J, Bepler G, Li J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 1;1006:167-178. doi: 10.1016/j.jchromb.2015.10.030. Epub 2015 Oct 31.

18.

Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.

Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ.

Cancer Immunol Res. 2015 Jul;3(7):777-86. doi: 10.1158/2326-6066.CIR-14-0175. Epub 2015 Feb 23.

19.

β-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition.

Pillai S, Trevino J, Rawal B, Singh S, Kovacs M, Li X, Schell M, Haura E, Bepler G, Chellappan S.

Cancer Res. 2015 Mar 15;75(6):1009-20. doi: 10.1158/0008-5472.CAN-14-0681. Epub 2015 Jan 19.

20.

Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.

Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.

J Thorac Oncol. 2014 Nov;9(11):1704-8. doi: 10.1097/JTO.0000000000000285.

Supplemental Content

Loading ...
Support Center